LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus pemetrexed in patients diagnosed with RET fusion-positive advanced non-small cell lung cancer (NSCLC). The findings showcased a notable improvement in progression-free survival (PFS), a primary objective of the study. Study […]

Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC

Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC

Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination with Merck’s Keytruda and platinum chemotherapy has been now approved by the US Food and Drug Administration (FDA) for the initial treatment of patients with metastatic, non-squamous, non-small cell lung […]

Dr. Reddy’s Laboratories launches Pemetrexed for Injection

Dr. Reddy’s Laboratories launches Pemetrexed for Injection

Dr. Reddy’s Laboratories said that it has launched Pemetrexed for Injection, 100 mg and 500 mg single-dose vials in the US market. Pemetrexed for Injection is the generic equivalent of ALIMTA (pemetrexed for injection), a chemotherapy drug approved by the US Food and Drug Administration (FDA). As per IQVIA Health, the ALIMTA brand and generic […]

FDA rejects Lilly’s sintilimab as first line treatment of NSCLC

FDA rejects Lilly’s sintilimab as first line treatment of NSCLC

The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small cell lung cancer (NSCLC). Lilly has been issued a complete response letter (CRL) for the BLA for the PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy. The US pharma […]

Zydus Cadila gets FDA nod for chemotherapy drug Pemetrexed generic

Zydus Cadila gets FDA nod for chemotherapy drug Pemetrexed generic

Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) for marketing Pemetrexed for Injection in 100mg/vial, 500mg/vial, and 1000mg/vial, single-dose vials. Pemetrexed for Injection is the generic for Eli Lilly and Company (Lilly) owned Pemetrexed, which is sold under Alimta and other […]